Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
about
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital.A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparisonAdverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatmentGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendationBaseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyPostinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection.Evaluation of olanzapine pamoate depot in seriously violent males with schizophrenia in the community.A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.Olanzapine pamoate for the treatment of schizophrenia.A review of olanzapine pamoate.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Drug safety evaluation of olanzapine pamoate.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study.Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being."Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.Olanzapine long-acting injection: insights from an early case series in the UK.Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Understanding depot antipsychotics: an illustrated guide to kinetics.Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.Psychiatric services: a platform for MTM.[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
P2860
Q33600259-3D6FF7E4-7743-42F1-AFD2-BBD55EC3DECAQ33857710-9F9A9111-C547-4A16-B1D4-E2CF4EDAD711Q34286350-29EC78C7-620E-49B0-B22D-8754F39CAF35Q34293855-68EA60DF-C5D6-4EDC-9493-9EADBEEC8869Q34293899-A3E0FF19-C126-4BA2-A617-D76C5144C877Q34315836-043E5BD5-71CF-4BF4-A2DC-173CF80C7E57Q34418833-49C10EB8-38B6-4750-853D-1E1A9B6DCFCFQ34546038-E2D3A2E3-18F2-45E9-8DB3-4115ADF2136BQ34720828-CB271E41-7769-4DB8-8DB3-5E0AA34B6B88Q34775426-14EB6180-1410-48D8-956B-A83F2FEB2991Q35030155-962BBB7F-347F-47C2-B90D-F50C09B96005Q35073474-C746439F-F128-46D6-B171-8BDC0786ABAEQ35321641-B62ADD6E-EAAC-4397-A749-3371DC4BFF7BQ35683860-EE62CE6A-1EBC-4360-8230-53031B5B09E3Q35841195-2DC1854A-067D-42AC-93E5-9B4921FC70ACQ37167256-8E695897-70B1-4760-BE2A-A0A8A7942A06Q37282220-E38E4108-49D9-43B7-AB08-B574A29B816AQ37501165-CEE8CD44-F23D-447A-BBED-31E574CBCEDCQ37831310-A9C23915-E62C-49CD-A9C7-C9A7557E9E0BQ38022638-0B3FE259-55E5-419B-BC8C-92DC35E0631CQ38115487-972A4EFD-AA08-4549-A1E9-1DCE464942BBQ38125213-25D27D10-E5C4-4703-9294-3D410624DC34Q38136262-31E0F50E-5422-442B-BE4B-680AB19AA25AQ38271353-46E23D94-8D27-4348-AEC2-E4DEACEC071CQ38622801-D07C3837-1B0B-466A-A6BD-CC871734658DQ38694855-3E0AD429-3A1B-48AF-9CDA-3DF647FD4C6AQ38696953-8F7F8772-CD14-4A0C-8925-5E92324A63C1Q38874076-1A38BDE5-C316-46FD-94BF-41E08A9F6360Q39207081-68E55E04-75A1-4C43-85F2-1C57F7C41883Q41641237-AD167276-56C4-482F-A750-2A40FA0A382CQ42520005-09D61526-14CE-426D-BFD5-1F3B52F95912Q42544159-82D25464-E9DE-4975-9513-A0422C89B872Q43952283-07DE7E65-D389-4268-8C88-1FDEE06E3EE4Q45769368-86F7FFAF-D740-4D7B-9250-C5BD01420EDAQ46837812-23554A44-EE2F-408B-9E86-91B6345ED395Q50602348-9A9977E8-A555-44A5-A797-65C915270AA1Q53654663-C6A7EC1E-1AB5-4BD1-8858-FC7844AC33FFQ54217848-AAA300D2-07BD-4F50-8BAC-269154C56C3D
P2860
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@ast
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@en
type
label
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@ast
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@en
prefLabel
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@ast
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@en
P2093
P2860
P356
P1433
P1476
Post-injection delirium/sedati ...... jection, I: analysis of cases.
@en
P2093
David P McDonnell
Elizabeth Brunner
Fangyi Zhao
Holland C Detke
Sara A Corya
Sebastian Sorsaburu
Victoria J Stefaniak
P2860
P2888
P356
10.1186/1471-244X-10-43
P577
2010-06-10T00:00:00Z
P5875
P6179
1044494907